ゼリア新薬工業の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2023/10/03 | 2,170 | 2,179 | 2,119 | 2,119 | -55 | -2.5% | 116,000 |
2023/10/02 | 2,202 | 2,228 | 2,174 | 2,174 | -45 | -2% | 135,400 |
2023/09/29 | 2,235 | 2,235 | 2,205 | 2,219 | -20 | -0.9% | 100,200 |
2023/09/28 | 2,255 | 2,273 | 2,223 | 2,239 | -66 | -2.9% | 121,700 |
2023/09/27 | 2,270 | 2,306 | 2,252 | 2,305 | +47 | +2.1% | 228,400 |
2023/09/26 | 2,278 | 2,287 | 2,254 | 2,258 | -46 | -2% | 166,800 |
2023/09/25 | 2,272 | 2,306 | 2,265 | 2,304 | +33 | +1.5% | 135,000 |
2023/09/22 | 2,282 | 2,299 | 2,260 | 2,271 | -31 | -1.3% | 115,000 |
2023/09/21 | 2,330 | 2,331 | 2,297 | 2,302 | -18 | -0.8% | 91,100 |
2023/09/20 | 2,363 | 2,380 | 2,320 | 2,320 | -52 | -2.2% | 114,600 |
2023/09/19 | 2,378 | 2,388 | 2,354 | 2,372 | -26 | -1.1% | 127,900 |
2023/09/15 | 2,247 | 2,400 | 2,247 | 2,398 | +1 | ±0% | 235,900 |
2023/09/14 | 2,400 | 2,405 | 2,391 | 2,397 | -24 | -1% | 110,600 |
2023/09/13 | 2,407 | 2,428 | 2,389 | 2,421 | -11 | -0.5% | 102,900 |
2023/09/12 | 2,381 | 2,432 | 2,381 | 2,432 | +36 | +1.5% | 132,000 |
2023/09/11 | 2,377 | 2,406 | 2,367 | 2,396 | +13 | +0.5% | 64,200 |
2023/09/08 | 2,400 | 2,412 | 2,372 | 2,383 | -36 | -1.5% | 67,100 |
2023/09/07 | 2,437 | 2,441 | 2,415 | 2,419 | -19 | -0.8% | 64,800 |
2023/09/06 | 2,465 | 2,465 | 2,419 | 2,438 | -30 | -1.2% | 69,400 |
2023/09/05 | 2,438 | 2,469 | 2,428 | 2,468 | +36 | +1.5% | 58,400 |
2023/09/04 | 2,431 | 2,444 | 2,422 | 2,432 | +8 | +0.3% | 58,200 |
2023/09/01 | 2,422 | 2,447 | 2,415 | 2,424 | +8 | +0.3% | 55,700 |
2023/08/31 | 2,407 | 2,428 | 2,407 | 2,416 | -2 | -0.1% | 45,700 |
2023/08/30 | 2,410 | 2,420 | 2,400 | 2,418 | +8 | +0.3% | 36,400 |
2023/08/29 | 2,418 | 2,418 | 2,397 | 2,410 | +4 | +0.2% | 20,500 |
2023/08/28 | 2,399 | 2,410 | 2,393 | 2,406 | +27 | +1.1% | 21,400 |
2023/08/25 | 2,369 | 2,386 | 2,366 | 2,379 | +5 | +0.2% | 22,100 |
2023/08/24 | 2,360 | 2,382 | 2,360 | 2,374 | +7 | +0.3% | 21,400 |
2023/08/23 | 2,347 | 2,370 | 2,346 | 2,367 | +1 | ±0% | 20,900 |
2023/08/22 | 2,343 | 2,366 | 2,333 | 2,366 | +28 | +1.2% | 23,600 |
2023/08/21 | 2,353 | 2,370 | 2,338 | 2,338 | +1 | ±0% | 27,300 |
2023/08/18 | 2,315 | 2,358 | 2,312 | 2,337 | -3 | -0.1% | 56,400 |
2023/08/17 | 2,367 | 2,378 | 2,326 | 2,340 | -49 | -2.1% | 50,100 |
2023/08/16 | 2,389 | 2,398 | 2,375 | 2,389 | -24 | -1% | 35,800 |
2023/08/15 | 2,413 | 2,428 | 2,399 | 2,413 | -11 | -0.5% | 56,300 |
2023/08/14 | 2,452 | 2,471 | 2,422 | 2,424 | -17 | -0.7% | 32,400 |
2023/08/10 | 2,418 | 2,441 | 2,405 | 2,441 | +29 | +1.2% | 26,900 |
2023/08/09 | 2,400 | 2,416 | 2,380 | 2,412 | +17 | +0.7% | 37,500 |
2023/08/08 | 2,361 | 2,400 | 2,360 | 2,395 | +34 | +1.4% | 33,100 |
2023/08/07 | 2,333 | 2,361 | 2,325 | 2,361 | +32 | +1.4% | 37,600 |
2023/08/04 | 2,330 | 2,350 | 2,310 | 2,329 | -31 | -1.3% | 63,500 |
2023/08/03 | 2,375 | 2,377 | 2,350 | 2,360 | -14 | -0.6% | 90,300 |
2023/08/02 | 2,380 | 2,397 | 2,368 | 2,374 | -7 | -0.3% | 64,100 |
2023/08/01 | 2,349 | 2,381 | 2,339 | 2,381 | +54 | +2.3% | 53,700 |
2023/07/31 | 2,374 | 2,374 | 2,318 | 2,327 | +3 | +0.1% | 68,100 |
2023/07/28 | 2,312 | 2,333 | 2,305 | 2,324 | -19 | -0.8% | 110,100 |
2023/07/27 | 2,308 | 2,344 | 2,308 | 2,343 | +16 | +0.7% | 60,200 |
2023/07/26 | 2,324 | 2,331 | 2,310 | 2,327 | -13 | -0.6% | 63,800 |
2023/07/25 | 2,371 | 2,371 | 2,332 | 2,340 | -23 | -1% | 45,100 |
2023/07/24 | 2,349 | 2,364 | 2,340 | 2,363 | +34 | +1.5% | 38,500 |
151~
200
件表示中 / 3457件
類似銘柄と比較する
現在ご覧いただいている「ゼリア新薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
ゼリア新薬 | 200,900円 | +9.6% | +17.5% | 2.29% | 11.35倍 | 1.11倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
杏林製薬 | 171,200円 | +3.2% | +4.5% | 3.04% | 19.67倍 | 0.75倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
ジーエヌアイ | 217,800円 | +52.1% | +23.3% | 0.00% | 15.39倍 | 3.21倍 |
|
創薬ベンチャー。米国で人工骨も。中国の特発性肺線維症薬で高シェア、米中に研究開発機能 |
栄研化 | 214,700円 | +7.6% | +57.5% | 2.47% | 16.58倍 | 1.63倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割弱。尿検査(ウロ)、遺伝子検査も育成 |
JCRファーマ | 62,200円 | -3.7% | -36.7% | 3.22% | 20.98倍 | 1.40倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
市場注目の銘柄
チャート関連のコラム